Pasithea therapeutics announces successful completion of pas-004 chronic toxicity studies

Pasithea completes chronic toxicity studies for pas-004, showing safety and potential for long-term use in nf1 and cancer treatment; phase 1 trial ongoing
KTTA Ratings Summary
KTTA Quant Ranking